Keyphrases
Lipopolysaccharide-induced
100%
Lipopolysaccharide
81%
Chemokine (C-C motif) Ligand 2 (CCL2)
56%
Inflammation
55%
Neuroinflammation
55%
Behavioral Impairment
50%
CXCL10
45%
Sickness
40%
Chemokine Expression
37%
Inflammatory Pathways
33%
Protective Effect
30%
Whole Brain
30%
Behavioral Deficits
27%
Brainstem
27%
Cerebellum
27%
Enzyme-linked Immunosorbent Assay (ELISA)
25%
Expression Activity
25%
Sickness Behavior
25%
Social Defeat
25%
Acute Effects
25%
Anti-neuroinflammation
25%
C57BL
22%
Inflammatory Chemokines
22%
Differential Effects
22%
Anxiety-like Behavior
22%
Astroglial Cells
20%
Open Field Test
20%
Mu-opioid Receptor Antagonist
20%
Female Mice
18%
Brain Hippocampus
17%
Brain Regions
17%
Potential Treatments
17%
Two-way Analysis of Variance
16%
Monocyte Chemoattractant protein-1 (MCP-1)
16%
Neurological Disorders
16%
Anti-inflammatory Effect
15%
Frontal Cortex
15%
Neuroprotective Effect
15%
Psychosocial Stress
13%
Dosing Schedule
13%
Continuation Treatment
12%
Treatment Development
12%
Central System
12%
Prefrontal Cortex
12%
Alzheimer's Disease
12%
Parkinson's Disease
12%
Large Intestine
12%
Liver
12%
Small Intestine
12%
Peripheral Inflammation
12%
Neuroscience
Lipopolysaccharide
100%
Chemokine
52%
CCL2
49%
CXCL10
38%
Behavior (Neuroscience)
34%
Blood Plasma
30%
Sickness Behavior
25%
Social Defeat
25%
μ-Opioid Receptor
16%
Brainstem
16%
Cerebellum
16%
Anti-Inflammatory
14%
In Vitro
14%
Narcotic Antagonist
14%
Hippocampus
13%
Neuroprotective Agent
12%
Monocyte Chemotactic Protein 1
11%
Elevated Plus Maze
10%
Neurological Disorder
9%
Frontal Lobe
8%
Interleukin 6
8%
Treatment Development
7%
Parkinson's Disease
7%
Prefrontal Cortex
7%
Alzheimer's Disease
7%
Inflammatory Bowel Disease
7%
Astrocyte
7%
Naltrexone
5%
Corticosterone
5%
Glial Fibrillary Acidic Protein
5%
Pharmacology, Toxicology and Pharmaceutical Science
Lipopolysaccharide
100%
Disease
78%
Chemokine
55%
Inflammation
48%
Lipopolysaccharide-Induced Neuroinflammation
34%
Neuroprotective Agent
15%
Mu Opiate Receptor Antagonist
15%
Enzyme-Linked Immunosorbent Assay
15%
Neurologic Disease
13%
Tumor Necrosis Factor
12%
Interleukin 6
12%
Monocyte Chemotactic Protein 1
10%
Alzheimer's Disease
9%
Preclinical Study
9%
Parkinson's Disease
9%
Antiinflammatory Activity
9%
Inflammatory Bowel Disease
9%
Cytokine
8%
Anti-Inflammatory Drug
8%
Interferon
6%
Beta Funaltrexamine
6%
C57BL 6 Mouse
6%
Naltrexone
5%
Gamma Interferon
5%
Gamma Interferon Inducible Protein 10
5%